MMP2 and central nervous system cancer: Moreover, the tumor subgroups in the patients from our collection and those from the TCGA GBM dataset with a higher MMP2 level also had shorter DFS and OS, indicating that the MMP2 level was a serviceable biomarker for prognosis‐based glioma subclassification.